台灣浩鼎生技股份有限公司
台灣浩鼎生技股份有限公司(OBI Pharma, Inc.)研發針對癌症需求之新藥。研發管線包括治療三陰性乳癌的 Adagloxad simolenin、肺癌藥物 OBI-833 及肝癌藥物 OBI-3424。此外涉及西藥批發與生物技術開發。公司成立於 2002 年,總部位於台灣台北。
該股 RSI(6) 為 84.3,處於超買區間,短線漲多宜留意回檔風險。股價站上5日、20日、60日、120日均線。KD 指標偏高(K=83.5),追高宜謹慎;MACD 柱狀體為正值,維持多方動能。 (自動產生 · 非投資建議)
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 09-24 | -1,136 | 0 | +2 | -1,135 |
| 09-23 | +793 | 0 | +10 | +792 |
| 09-22 | -341 | 0 | +2 | -356 |
| 09-21 | +187 | 0 | +30 | +202 |
| 09-18 | -406 | 0 | +3 | -405 |
| 09-17 | +261 | 0 | +3 | +260 |
| 09-16 | +84 | 0 | +1 | +85 |
| 09-15 | +141 | 0 | +1 | +141 |
| 09-14 | +36 | 0 | 0 | +36 |
| 09-11 | -82 | 0 | 0 | -82 |
| 09-10 | +13 | 0 | 0 | +13 |
| 09-09 | +82 | 0 | +1 | +83 |
| 09-08 | +214 | 0 | +1 | +214 |
| 09-07 | +22 | 0 | +1 | +22 |
| 09-04 | +167 | 0 | +1 | +167 |
| 09-03 | -238 | 0 | 0 | -238 |
| 09-02 | -86 | 0 | 0 | -86 |
| 09-01 | -301 | 0 | 0 | -301 |
| 08-31 | -182 | 0 | +1 | -182 |
| 08-28 | -39 | 0 | 0 | -39 |
| 08-27 | -50 | 0 | 0 | -50 |
| 08-26 | +6 | 0 | +4 | +7 |
| 08-25 | -46 | 0 | 0 | -46 |
| 08-24 | -88 | 0 | 0 | -88 |
| 08-21 | -17 | 0 | 0 | -17 |
| 08-20 | +230 | 0 | +1 | +230 |
| 08-19 | -11 | 0 | 0 | -11 |
| 08-18 | +40 | 0 | 0 | +40 |
| 08-17 | -100 | 0 | 0 | -100 |
| 08-14 | -16 | 0 | 0 | -16 |
| 08-13 | +65 | 0 | 0 | +64 |
| 08-12 | -36 | 0 | 0 | -36 |
| 08-11 | +139 | 0 | 0 | +139 |
| 08-10 | +110 | 0 | 0 | +110 |
| 08-07 | +36 | 0 | 0 | +36 |
| 08-06 | -23 | 0 | +2 | -23 |
| 08-05 | +31 | 0 | 0 | +31 |
| 08-04 | -109 | 0 | 0 | -109 |
| 08-03 | +3 | 0 | +3 | +3 |
| 07-31 | -106 | 0 | 0 | -106 |
| 07-30 | -22 | 0 | 0 | -22 |
| 07-29 | +189 | 0 | +12 | +189 |
| 07-28 | -41 | 0 | 0 | -41 |
| 07-27 | -26 | 0 | 0 | -26 |
| 07-24 | +9 | 0 | 0 | +9 |
| 07-23 | -49 | 0 | 0 | -49 |
| 07-22 | +32 | 0 | 0 | +32 |
| 07-21 | -52 | 0 | 0 | -52 |
| 07-20 | +122 | 0 | 0 | +121 |
| 07-17 | -93 | 0 | +2 | -93 |
| 07-16 | -20 | 0 | +2 | -19 |
| 07-15 | +188 | 0 | 0 | +188 |
| 07-14 | +14 | 0 | +2 | +14 |
| 07-13 | -107 | 0 | 0 | -107 |
| 07-09 | +158 | 0 | 0 | +158 |
| 07-08 | -12 | 0 | 0 | -12 |
| 07-07 | +72 | 0 | 0 | +72 |
| 07-06 | -219 | 0 | 0 | -219 |
| 07-03 | +49 | 0 | +14 | +49 |
| 07-02 | -53 | 0 | 0 | -53 |
| 07-01 | -17 | 0 | +2 | -17 |
| 06-30 | -275 | 0 | 0 | -279 |
| 06-29 | +373 | 0 | +12 | +377 |
| 06-26 | -464 | 0 | +6 | -465 |
| 06-25 | -187 | 0 | 0 | -187 |
| 06-24 | -75 | 0 | +2 | -75 |
| 06-23 | +9 | 0 | +6 | +9 |
| 06-22 | -31 | 0 | 0 | -31 |
| 06-18 | +15 | 0 | 0 | +15 |
| 06-17 | +29 | 0 | 0 | +29 |
| 06-16 | -24 | 0 | 0 | -24 |
| 06-15 | -39 | 0 | 0 | -39 |
| 06-12 | +146 | 0 | 0 | +146 |
| 06-11 | +29 | 0 | 0 | +29 |
| 06-10 | -45 | 0 | 0 | -45 |
| 06-09 | +6 | 0 | 0 | +6 |
| 06-08 | +93 | 0 | 0 | +93 |
| 06-05 | +29 | 0 | 0 | +29 |
| 06-04 | -64 | 0 | 0 | -64 |
| 06-03 | +79 | 0 | 0 | +79 |
| 06-02 | +1 | 0 | +2 | +1 |
| 06-01 | +23 | 0 | 0 | +23 |
| 05-29 | -8 | 0 | 0 | -8 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/04 | 345 萬 | +30.7% | -32.8% |
| 2026/03 | 264 萬 | +65.6% | -9.8% |
| 2026/02 | 159 萬 | +19.5% | -85.5% |
| 2026/01 | 133 萬 | -81.9% | +140.2% |
| 2025/12 | 738 萬 | -7.0% | -5.9% |
| 2025/11 | 793 萬 | +43.7% | +306.2% |
| 2025/10 | 552 萬 | +3.2% | +215.0% |
| 2025/09 | 535 萬 | +401.4% | +14.8% |
| 2025/08 | 107 萬 | -74.0% | -82.0% |
| 2025/07 | 410 萬 | +5.8% | -66.8% |
| 2025/06 | 388 萬 | +3.5% | -51.8% |
| 2025/05 | 375 萬 | - | -43.9% |